Navigation Links
Theratechnologies: TH9507 Phase 3 Clinical Update

- Data from first Phase 3 trial presented at ENDO 2007

- Regulatory approvals for second Phase 3 trial open the door for patient recruitment in Europe

MONTREAL, QUEBEC -- (MARKET WIRE) -- June 04, 2007 -- Theratechnologies (TSX: TH) reported today that 26-week data from its first Phase 3 study testing TH9507 in HIV-associated lipodystrophy were presented today in Toronto at ENDO, the 89th annual meeting of the Endocrine Society. The presentation was made by Dr. Steve Grinspoon, Associate Professor of Medicine, Harvard Medical School and lead investigator for the TH9507 trial in the United States.

Positive 26-week results were recently presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI). The primary endpoint and important secondary endpoints were achieved. The study was powered to detect an 8% reduction in visceral adipose tissue (VAT) versus placebo. After 26 weeks, patients on TH9507 achieved a 15% reduction in VAT versus baseline and a 20% difference versus placebo. In general, TH9507 was shown to be well tolerated by patients.

Dr. Grinspoon´s presentation today particularly highlighted beneficial effects of TH9507 on key metabolic parameters known to be risk factors for cardiovascular diseases, suggesting that strategies using a growth hormone releasing factor will reduce abdominal obesity and may lower cardiovascular risk in HIV patients.

Since the initiation of the trial in January, Theratechnologies has obtained regulatory approval in five European countries for its second Phase 3 clinical study testing TH9507 in HIV-associated lipodystrophy. Patients are being enrolled for the study in Belgium, France, Italy, Spain and the United Kingdom. North American recruitment previously began in the United States in January and Canadian recruitment began in May.

The second Phase 3 trial is a 400-patient, multi-center, double-blind, randomized, placebo-con
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Theratechnologies Phase Clinical Update
(Date:12/17/2014)... 2014 Revenue and earnings above the ... and development In the past 2013/14 fiscal year ... percent to EUR 4.287 billion (last year: EUR 4.190 billion) ... to EUR 360 million. "Overall, 2013/14 was a successful fiscal ... , President and CEO of Carl Zeiss AG. "Thanks to ...
(Date:12/17/2014)... , Dec. 17, 2014 With advancements ... the MRI market is seeing new growth, according ... MRI scans account for the majority of market ... resolution of images, which are creating opportunities for more ... market is growing at a rate of 4%, ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
(Date:12/21/2014)... CA (PRWEB) December 21, 2014 The Oncology ... drive in the Santa Ana and Whittier offices. The Hope ... brighten the lives of patients and their families during the ... reach out to approximately 70 children between both offices. This ... the help of Target’s community service team, store managers and ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly bamboo ... its bamboo flooring promotion for the coming 2015. ... suppliers, and offers the best bamboo products and ... promotion, all customers can enjoy a special discount, ... know BambooIndustry.com from press releases. , The bamboo ...
(Date:12/20/2014)... 20, 2014 An improving macroeconomic landscape ... benefited the Massage Services industry over the ... industry products, the anticipated 1.0% annualized increase in per ... consumers with the means to afford additional massages. “While ... massage in a given year has declined from 2009 ...
(Date:12/20/2014)... The print component of Healthy Aging is ... approximately 160,000 copies and an estimated readership of 420,000. ... social media strategy and across a network of top ... version of the campaign, click here . , ... ladies of CTV’s The Social. Lainey Lui, Melissa ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2
... for new mothers, according to a study in the ... researcher Dr. Robert Whitaker. , While smoking and ... also affect the health of her child, Whitaker said. ... smoking include sudden infant death, asthma, ear infections and ...
... awareness of Molluscum Contagiosum, CHARLES TOWN, W.V., ... RBRM) a provider of treatment for diabetic,peripheral neuropathy ... the month of October 2007; increase is 12% ... "As public awareness of the dangers related ...
... YORK, Nov. 26 /Xinhua-PRNewswire-FirstCall/ -- itLinkz Group, Inc.,("ILKZ") ... beginning of,trading today, November 26, 2007, the Company ... Inc." and began trading under its new,symbol (OTC ... a,1:28 reverse split of its outstanding common shares ...
... Giesing, Chief Scientific,Officer and Terry Nida, Chief Operating ... (http://www.urigen.com ) will be featured in an,exclusive ... 27 at 10:30,a.m. EST. The interview will be ... EST on,November 27., The interview will cover ...
... 26, 2007) Rutgers College of Nursing faculty member ... of the Rutgers-Newark Provosts Award for Community Engagement in ... significance based in whole or in part on data ... Diner, Rutgers-Newark provost, established the Provosts Awards for Community ...
... technology allows medical professionals to instantly ... access and manipulate ... a global leader in,software-driven systems for targeted, less-invasive medical ... at the,Annual Meeting of the Radiological Society of North ...
Cached Medicine News:Health News:Smoking and depression often co-occur in new mothers 2Health News:ReBuilder Medical Technologies, Inc. Announces Record Sales Month 2Health News:itLinkz Group, Inc. Changes Name to China YCT International Group, Inc. and Effects Reverse Stock Split 2Health News:WallSt.net Announces Upcoming Interview with CSO and COO of Urigen Pharmaceuticals 2Health News:Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers-Newark Provost Award 2Health News:Digital Lightbox(C) Unlocks New Possibilities in Collaborative Patient Treatment 2Health News:Digital Lightbox(C) Unlocks New Possibilities in Collaborative Patient Treatment 3
... to facilitate an arthrodesis, either by an ... cages allowing radicular compression by restoring the ... of the foramina, which in turn enhances ... major lumbar instabilities.,CC cages are made of ...
... The PACHETT 3 uses the exact enhanced ... the DGH pachymeters used exclusively by the ... built into the software. The new backlit ... running average, standard deviation and IOP correction ...
... Already, the most advanced motor driven ... easier and faster to learn and operate. ... maintaining accuracy and precision. Our software makes ... easy transition from manual instruments or other ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
Medicine Products: